ESMO Congress Round-Up With Dr. Evan Yu: EV-302 and CheckMate 901

In the first part of this ESMO Congress round-up video series, Evan Yu, MD, of the Fred Hutchinson Cancer Center, opines on whether the data from EV-302 and CheckMate 901 are truly practice-changing.

He also offers his thoughts on the circumstances in which physicians should recommend one combination therapy over the other.

View Dr. Yu’s further thoughts on PSMAfore and LITESPARK-005.